Ardena

Kempen is proud to announce it has advised Ardena / Mentha capital in the acquisition of ABL 

Contract development and manufacturing organisation (CDMO) owned by Mentha Capital

• Acquisition of Netherlands-based ABL follows the merging of Pharmavize and Crystallics to form Ardena and broadens the CDMO’s pre-clinical and clinical offering to include bioanalytical and drug discovery services
• Ardena now has three facilities in Europe, including Amsterdam (the former Crystallics facility) and Assen (the former ABL facility) in the Netherlands, as well as the company’s headquarters in Ghent, Belgium
• Kempen acted as financial adviser to Ardena / Mentha Capital in the acquisition of ABL